4//SEC Filing
DAmour Kevin 4
Accession 0001140361-21-023007
CIK 0000748592other
Filed
Jun 29, 8:00 PM ET
Accepted
Jun 30, 9:34 PM ET
Size
8.2 KB
Accession
0001140361-21-023007
Insider Transaction Report
Form 4
DAmour Kevin
See Remarks
Transactions
- Award
Restricted Stock Unit
2021-06-28+70,290→ 70,290 totalExp: 2031-06-28→ Common Stock (70,290 underlying) - Award
Stock Option
2021-06-28+140,580→ 140,580 totalExercise: $21.35Exp: 2031-06-28→ Common Stock (140,580 underlying)
Footnotes (3)
- [F1]The option vests and becomes exercisable over four years, with twenty-five percent of the shares covered thereby vesting on June 28, 2022, and 1/36 of the remaining shares covered thereby vesting on the 28th day of each calendar month from July 28, 2022 through June 28, 2025, subject to continued service through each vesting date.
- [F2]Each restricted stock unit represents a contingent right to receive one share of common stock.
- [F3]The Restricted Stock Unit vests and becomes exercisable in four equal installments on June 28 of each of 2022, 2023, 2024 and 2025, provided they shall vest in full immediately prior to a Change in Control (as defined in Dr. D'Amour's Executive Employment Agreement, dated as of June 5, 2021 and effective as of June 28, 2021), subject to continued service through each vesting date.
Documents
Issuer
Brooklyn ImmunoTherapeutics, Inc.
CIK 0000748592
Entity typeother
Related Parties
1- filerCIK 0001870486
Filing Metadata
- Form type
- 4
- Filed
- Jun 29, 8:00 PM ET
- Accepted
- Jun 30, 9:34 PM ET
- Size
- 8.2 KB